Get the Stockscreener App
31.47
0.10%
0.03
After Hours:
31.45
-0.02
-0.06%
Catalyst Pharmaceuticals Inc stock is traded at $31.47, with a volume of 1.36M.
It is up +0.10% in the last 24 hours and up +0.64% over the past month.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$31.44
Open:
$31.45
24h Volume:
1.36M
Relative Volume:
0.61
Market Cap:
$3.85B
Revenue:
$596.96M
Net Income/Loss:
$221.32M
P/E Ratio:
18.09
EPS:
1.7397
Net Cash Flow:
$208.13M
1W Performance:
+0.16%
1M Performance:
+0.64%
6M Performance:
+35.94%
1Y Performance:
+46.71%
1-Day Range:
$31.44
$31.47
1-Week Range:
$31.41
$31.50
52-Week Range:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.47 | 3.85B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
528.02 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.00 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Santhera Pharmaceuticals Holding AG - Via Ritzau
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan
Catalyst reports Phase 1 vamorolone study results - Investing.com
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times
Catalyst's rare-disease steroid showed immune activity without the usual suppression - Stock Titan
Monolithic Power Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Monolithic Power Systems, Inc.MPWR - Business Wire
Skeletal Nickel Catalyst Market Growth to Accelerate by 2035 Amid Rising Pharma DemandNews and Statistics - IndexBox
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
Quantified Common Ground Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In - Sahm
Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x - TechStock²
Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Understanding the Setup: (CPRX) and Scalable Risk - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Nationwide Renaissance Small Cap Growth Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals stock edges higher to 31.41 after patient summit event, CatalystForRare - Traders Union
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - Business Wire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill
Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing - Minichart
Catalyst Pharma Gains FTC Clearance for Angelini Merger - TipRanks
Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026 - TradingView
HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger - Stock Titan
Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares - AD HOC NEWS
Catalyst Pharmaceuticals Inc (CPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Catalyst Pharmaceuticals Inc - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SMID Core Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Institutional Confidence - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
The Technical Signals Behind (CPRX) That Institutions Follow - Stock Traders Daily
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout - Law360
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Angelini Pharma to buy Catalyst (CPRX) for $31.50 per share; virtual vote July 8 - Stock Titan
Catalyst Pharmaceuticals | DEFM14A: Definitive proxy statement relating to merger or acquisition - Moomoo
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
Dakota Review Highlights Broad-Based Strength in May 2026 Private Markets Activity - TipRanks
Homogeneous Catalyst Market Growth Outlook to 2035: Trends, Drivers, and Regional AnalysisNews and Statistics - IndexBox
Precision Trading with Catalyst Pharmaceuticals Inc. (CPRX) Risk Zones - Stock Traders Daily
CPRX PE Ratio & Valuation, Is CPRX Overvalued - Intellectia AI
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer - news.financial
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
D.R. Horton Inc. (DHI) Q1 2026 Earnings: Slight EPS Beat Amid Mixed Housing ConditionsEarnings Growth Analysis - thelegaladvocate.com
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):